10:20 AM EST, 11/10/2025 (MT Newswires) -- MeiraGTx ( MGTX ) said Monday it is partnering with Eli Lilly ( LLY ) to develop and commercialize genetic therapies for eye diseases.

The company said it will give Eli Lilly ( LLY ) global rights to its AAV-AIPL1 program, which targets Leber congenital amaurosis 4, a severe inherited eye disorder. In an AAV-AIPL1 trial with 11 legally blind children, all participants gained their vision after therapy, according to MeiraGTx ( MGTX ).

Eli Lilly ( LLY ) will also gain certain rights to MeiraGTx's ( MGTX ) gene therapy and riboswitch technologies for use in ophthalmology, MeiraGTx ( MGTX ) said.

MeiraGTx ( MGTX ) will receive $75 million upfront and could earn more than $400 million in milestone payments, plus tiered royalties on future products, the company said.

Price: 9.37, Change: +0.90, Percent Change: +10.63